Digerati Technologies, Inc. to present at NobleCon18 – Hard Rock / Guitar Hotel Miami – April 20 & 21




Digerati Technologies, Inc. to present at NobleCon18 – Hard Rock / Guitar Hotel Miami – April 20 & 21

Research, News, and Market Data on Digerati Technologies

 

Digerati Technologies, Inc. is one of the selected companies to present at NobleCon18 at the Hard Rock/The Guitar Hotel, April 19-21 located just minutes from Fort Lauderdale and Miami International Airports. Admission is free for investors at any and every level – institutional, family office, investment advisors, independent brokers, equity analysts, and even novice self-directed investors. Please register at the following link and mention Digerati Technologies, Inc. in the referral section: 
https://www.nobleconference.com/register/investor-guest. In addition to corporate presentations, scheduled breakouts, and one-on-one opportunities, expect world-class keynotes, panels and firesides, and multiple networking opportunities.

About Digerati Technologies, Inc.

Digerati Technologies, Inc. (OTCQB: DTGI) is a provider of cloud services specializing in UCaaS (Unified Communications as a Service) solutions for the business market. Through its operating subsidiaries T3 Communications (T3com.com), Nexogy (Nexogy.com), SkyNet Telecom (Skynettelecom.net) and NextLevel Internet (nextlevelinternet.com), the Company is meeting the global needs of small businesses seeking simple, flexible, reliable, and cost-effective communication and network solutions including cloud PBX, cloud telephony, cloud WAN, cloud call center, cloud mobile, and the delivery of digital oxygen on its broadband network. The Company has developed a robust integration platform to fuel mergers and acquisitions in a highly fragmented market as it delivers business solutions on its carrier-grade network and Only in the Cloud™. For more information, please visit www.digerati-inc.com and follow DTGI on LinkedIn, Twitter and Facebook.

 

Facebook: Digerati Technologies, Inc.

Twitter: @DIGERATI_IR

LinkedIn: Digerati Technologies, Inc.

SEC Climate Change Disclosure Rules and Challenges



Image Credit: Rakicevic Nenad (Pexels)


SEC Proposes Far-Reaching Climate Disclosure Rules for Companies – Here’s Where the Rules May be Vulnerable to Legal Challenges

 

The U.S. Securities and Exchange Commission released its long-awaited proposal to require companies to disclose their climate risks to investors, and it’s arguably the most significant action on climate change yet under the Biden administration.

SEC Commissioner Allison Herren Lee called it a “watershed moment for investors and financial markets.” It is also a win for President Joe Biden, whose other climate efforts have struggled. A year ago, Biden appointed an SEC chairman, Gary Gensler, who supports climate disclosures in principle.

The proposed requirements, once finalized, could help climate-conscious investors more accurately direct their money to businesses that are responding to climate risks, simultaneously strengthening both markets and the nation’s climate response.

 

This article was republished with permission from The Conversation, a news site dedicated to sharing ideas from academic experts. It represents the research-based findings and thoughts of Daniel E. Walters, Assistant Professor of Law, Penn State and William M. Manson, Law Student, Penn State.

 

But the proposal has a long way to go before it can make the transformative changes it aims for. We study climate regulation and business law and have closely tracked debates over the proposal. Here’s what you need to know.

What the Rule Would Do

If the SEC votes to finalize the rule after a public comment period, it would standardize, extend and mandate disclosure requirements that the SEC encouraged in a guidance document back in 2010.

As the 510-page notice released on March 21, 2022, makes clear, companies would be expected to include a laundry list of items in their regular filings with the SEC: information on the company’s “oversight and governance of climate-related risks,” any expected climate-related risks it faces in the future, any transition plans the business has developed, and data on certain greenhouse gas emissions linked to the company’s operations, among other things.

Gensler said the proposal draws from the approach of the Task Force on Climate-Related Financial Disclosure, which several countries have adopted. But the proposal is still noticeably less stringent than the European Union’s regulations.

In the leadup to the release of the SEC’s proposal, supporters and opponents speculated about whether so-called Scope 3 emissions would be required. Under the terms of the proposal, the answer is a resounding “maybe.”

A company’s Scope 3 emissions result from activities of third parties, such as the emissions produced by its suppliers or, ultimately, by its consumers. As the SEC pointed out, these emissions can “represent a majority of the carbon footprint for many companies.”

 

Graphic:
Chester Hawkin/Center for
American Progress

 

While all registered companies would be required to disclose their own direct greenhouse emissions, such as emissions from manufacturing processes, as well as indirect emissions through the use of energy – Scopes 1 and 2, respectively – only some companies would need to report Scope 3 emissions under the proposal.

The proposal would exempt “small reporting companies” from Scope 3 reporting. It would allow large companies to withhold Scope 3 emissions data when the company determines that the data are not “material” to investors or if the company doesn’t have Scope 3 emissions targets or goals.

Public interest groups wanted the SEC to require disclosure of even non-material Scope 3 emissions, while industry groups pushed for the SEC to forgo any Scope 3 emissions mandate. The SEC appears to have split the baby.

It’s Not Over ‘til it’s Over

The SEC’s proposal initiates what can be a perilous process of public vetting before the rule goes into effect.

First, the SEC will take public comments on the proposal for the next 60 days. The agency received about 600 unique comments in its request for information before issuing the proposal. Now, with more details available, there should be substantially more engagement. When the Federal Communications Commission took public comment on its proposal to roll back net neutrality rules, it received almost 22 million comments.

The SEC should expect to receive extensive comments both from opponents of any regulation and public interest groups that want more stringent regulations.

Under standard administrative law principles, the SEC must consider and respond to any important arguments or data presented by public commenters. If it gets even a fraction of the comments the FCC got, this process could easily take half a year.

By design, this process is supposed to allow the SEC to change the terms of the proposal, although it cannot change the proposal so much that the public would not have understood during the comment period what the final rule would do.

 

The Courts Lie in Wait

Now that the terms of the proposed rule are in place, it is easier to see where legal vulnerabilities might be.

Industries are likely to take issue with the SEC’s estimates of the costs companies will face to comply with the rules. The SEC’s proposal states that the cost could be “relatively small” if companies already provide similar information. The SEC will have to defend that assertion carefully.

In 2011, the U.S. Court of Appeals for the District of Columbia threw out an SEC rule on the grounds that it failed to adequately consider economic costs of compliance. Although that ruling has been widely criticized for imposing a cost-benefit analysis requirement that is not required by law, the U.S. Supreme Court seems sympathetic to such a requirement.

Another vulnerability will stem from the SEC’s approach to Scope 3 emissions.

Both industries and public interest groups are likely to argue that the SEC misunderstood its statutory authorization – either because it included Scope 3 emissions or because it believed it was limited to “material” emissions, respectively. Or challengers could argue that SEC failed to fully analyze policy considerations favoring a different approach. How well the SEC responds to critical comments will be important when the courts are asked to decide if the SEC acted in an arbitrary or capricious or unlawful manner.

Finally, it is possible that the matter is out of the SEC’s hands. Some critics have suggested that the regulation of climate disclosures is too important a question for regulators and belongs with Congress. Courts have sometimes shown skepticism toward agency actions that present so-called “major questions,” including those related to climate change.

If the courts view climate disclosure as a major question, they may vacate the rule even if the SEC has strongly supported its approach.

 

A Long Way to Go

The SEC has taken a major step that could boost the Biden administration’s climate change agenda, but whether it will be able to navigate a treacherous administrative and legal process without changing its approach remains to be seen.

The notice of proposed rulemaking is usually just the opening offer in an ongoing negotiation over the rule.

 

Suggested Reading



SEC Cryptocurrency ETFs are Not Getting Decided Upon on Schedule



The Importance of Dependable Energy, Even Nuclear, is Heightened in Recent War





Delta Air Lines Signs 75 Million Gallon Per Year Agreement with Gevo



Gevo Inc. C-Suite Interview (Video)

 

Stay up to date. Follow us:

 

electroCore Announces Dr. Peter Staats to Keynote the Fifth Annual Bioelectronic Medicine Forum in New York



electroCore Announces Dr. Peter Staats to Keynote the Fifth Annual Bioelectronic Medicine Forum in New York

News and Market Data on electroCore

 

ROCKAWAY, N.J.
March 23, 2022 (GLOBE NEWSWIRE) — 
electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced its co-founder and Chief Medical Officer, Dr.  Peter Staats, will keynote the Fifth Annual 
Bioelectronic Medicine Forum on 
April 5, 2022.

The event will take place in 
New York City and will cover a range of technologies and indications for bioelectronic medicine, including applications in cardiovascular medicine, inflammation, gastrointestinal disorders, and many other clinical specialties.

Other panelists and presenters at the 2022 event include Marom Biksom, Professor of Biomedical Engineering at 
City College of New YorkImran Eba, partner at 
Action Potential Venture Capital; and  Eric Van Gieson, Ph.D., Program Manager at DARPA Biological Technologies Office; and prior keynote speakers include  Murthy Simhambhatla, the President and CEO of 
SetPoint Medical.

Dr. Staats is the former President of the 
North American Neuromodulation Society
American Society of Interventional Pain Physicians
New Jersey Society of Interventional Pain Physicians, and the 
Southern Pain Society. He is currently President of the 
World Institute of Pain and continues to serve as Chief Medical Officer for National Spine and Pain Centers, the largest pain practice in 
the United States, and electroCore, Inc.

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

Investors:
Rich Cockrell

CG Capital
404-736-3838
ecor@cg.capital

Onconova Therapeutics To Present At The Next Generation Kinase Inhibitors Summit



Onconova Therapeutics To Present At The Next Generation Kinase Inhibitors Summit

News and Market Data on Onconova Therapeutics

 

NEWTOWN, Pa., March 23, 2022 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Adar Makovski Silverstein, Ph.D., Director of Corporate Development for Onconova, will present a high-level overview of the Company’s narazaciclib program at the Next Generation Kinase Inhibitors Summit on March 30, 2022, at 2:00 p.m. ET.

Also in connection with the summit, Dr. Steven Fruchtman, President & CEO of Onconova, will co-chair a pre-conference workshop entitled “Harnessing Effective Translational & Clinical Strategies to Prevent Future Safety Issues and Accelerate Kinase Inhibitor Development to Cover Unmet Needs in Humans,” on March 29, 2022, from 1:00 – 4:00 p.m. ET. Both the summit and pre-conference workshop will take place at Boston Park Plaza in Boston, Massachusetts. Those interested in registering for the summit can do so here.

About the Next Generation Kinase Inhibitors Summit

The inaugural Next Generation Kinase Inhibitors Summit is the only industry-focused meeting dedicated to applying novel kinase biology to drug development and innovating existing programs to produce the next wave of kinase inhibitor drugs which are able to show efficacious and durable clinical response in oncology and beyond. The summit is expected to include 60+ senior drug developers, 20+ speakers, 1 deep-dive workshop, and over 3 days of unrivalled content spanning discovery, R&D and clinical development.

About Onconova Therapeutics

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China.

Onconova’s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

For more information, please visit www.onconova.com.

Company Contact:
Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/www.onconova.com/contact/

Investor Contact:
Bruce Mackle
LifeSci Advisors
929-469-3859
bmackle@lifesciadvisors.com

PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call



PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call

Research, News, and Market Data on PDS Biotech

 

FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that it has changed the date of its previously announced 2021 fourth quarter and full year earnings release call from Wednesday, March 23, 2022 to 8:00 AM EDT on Thursday, March 31, 2022 as PDS Biotech needs additional time to complete its audit and file its Annual Report on Form 10-K for the fiscal year ended December 31, 2021. Following the release, management will host a conference call to review the financial results and provide a business update.

Thursday, March 31, 2022, 8:00 AM Eastern Daylight Time
Domestic: 877-407-3088
International: 201-389-0927
Webcast: PDS Biotechnology Earnings Webcast

A live webcast of the conference call will also be available on the investor relations page of the Company’s website at www.pdsbiotech.com. After the live webcast, the event will be archived on PDS Biotech’s website for six months.

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.

Our Infectimune™ -based vaccines have demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T-cell responses including long-lasting memory T-cell responses. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
pdsb@cg.capital

Taxpayer-Funded Study on Cannabis and Chronic Pain



Image: Agency for Healthcare Research and Quality (DHHS)


Ongoing Federal Review on Cannabis and Pain Shows Some Relief

 

Does medical marijuana have the potential to help reduce opioid use in chronic pain patients? Late in 2020, a U.S. Government agency set out to answer two questions related to cannabis and pain. First, what if any benefits there are in using cannabinoids for chronic pain, and second, what are the harms of cannabinoids? This week they released results from this round of testing.

 

The Test

The Agency for Health and Research Quality (AHRQ) is one of many agencies under the Department of Health and Human Services. Their cannabis ‘living’ systematic review (continually updated) assesses the effectiveness and harms of cannabis and other plant-based treatments for chronic pain conditions. This first review used plant-based compounds (PBCs) similar to opioids with potential for addiction, misuse, and serious adverse effects and measured them against other PBCs such as cannabis derivatives. The findings are intended for policymakers, financiers, chronic pain researchers, and clinicians who treat pain.

The report for the living systemic review will be updated quarterly.

 

The Review

This was the AHRQ’s first study for the ongoing living systematic review on cannabis and other plant-based treatments for chronic pain. Researchers grouped cannabis-related products based on their tetrahydrocannabinol (THC) to cannabidiol (CBD) ratio using the categories: high-THC to CBD, comparable THC to CBD, and low-THC to CBD (including CBD only). Not included in this study, a new placebo-controlled randomized controlled trial (RCT) of oral CBD1 and an observational study of plant-based comparable THC to CBD versus synthetic CBD. This added to a total of 21 RCTs and 8 observational studies. In patients with chronic (mainly neuropathic) pain with short-term treatment (4 weeks to <6 months).

 

The Results (Small, Medium, Large)

The AHRQ review suggests comparable THC to CBD ratio oral spray is associated with small improvements in pain severity and overall function versus a placebo. There was no increase in the risk of serious adverse events or withdrawal due to any events. Potentially, there is a high increased risk of dizziness and sedation and a moderately increased risk of nausea.

Results measured after testing synthetic THC to CBD suggest moderate improvement in pain severity, no effect on overall function and increased risk of sedation, as well as a large increased risk of nausea versus a placebo. The synthetic THC is probably associated with the large increased risk of dizziness, according to the reported results.

The extracted whole-plant high THC to CBD ratio combination while offering some relief, may be associated with large increases in the risk of study withdrawal due to adverse events and dizziness versus placebo.

Whole plant and “patient’s choice” choice products low in THC to CBD produced insufficient findings to draw any conclusion.

Not reported in the report were other adverse outcomes such as psychosis, cannabis use disorder, cognitive deficits, and outcomes on the impact cannabinoid use has on the use of opioids.

 

Take-Away

One of the many potential medical uses of marijuana is pain relief. This has become particularly important as it’s desirable to have safer alternatives to opioid-based pain relievers. Taxpayer-funded research on pain relief is ongoing at the AHRQ. The agency will be reporting its findings quarterly. The most recent review, albeit a very small sample size, found various THC:CBD ratios provided different levels of relief and different risk levels.

 

Paul
Hoffman

Managing Editor, Channelchek

 

Suggested Reading



Opportunities in the Rapidly Growing Pain Management Sector



The NFL is Providing Funds for a Marijuana Study Related to Injured Athlete Use





The Future of Cannabis Crosses Many Industries



Federal Law Questions Still Loom for the Cannabis Industry

Sources

https://effectivehealthcare.ahrq.gov/products/plant-based-chronic-pain-treatment-annual-update/draft-comment

https://effectivehealthcare.ahrq.gov/products/plant-based-chronic-pain-treatment/living-review

https://effectivehealthcare.ahrq.gov/products/plant-based-chronic-pain-treatment/protocol

https://effectivehealthcare.ahrq.gov/products/form/plant-based-chronic-pain-treatment-annual-update

 

Stay up to date. Follow us:

 

Ocugen Announces Appointment Of Marna C. Whittington, PhD, To Board Of Directors



Ocugen Announces Appointment Of Marna C. Whittington, PhD, To Board Of Directors

Research, News, and Market Data on Ocugen

 

MALVERN, Pa., March 23, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced the appointment of Marna C. Whittington, PhD, to the Board of Directors. Her term became effective March 21, 2022.

“We’re extremely pleased to welcome Dr. Marna Whittington to the Ocugen board,” said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen. “Her experiences will be exceedingly important to our growth strategy as we progress our modifier gene therapies and vaccine candidate. I also want to thank Manish Potti for his significant contributions to the Board and the Company.”

Mr. Potti made the personal decision not to seek another term of service on the Board of Directors, commenting, “Ocugen is uniquely positioned for a bright future. Its pipeline and clinical programs for COVID-19 and ophthalmology are going to be valuable additions for patients. Shankar and the management team are well-prepared to handle the road ahead of them, and I wish the company nothing but continued success.”

Dr. Whittington is a renowned leader within the financial sector and a sought-after expert serving on numerous boards. She was the Chief Executive Officer of Allianz Global Investors Capital from 2001 until her retirement in January 2012. Before that, Dr. Whittington was a corporate officer for Morgan Stanley Investment Management and the University of Pennsylvania as well as the Secretary of Finance for the State of Delaware. She currently serves on the boards of the Salk Institute, Tower Hill School, Macy’s Inc., the Philadelphia Contributionship (a company founded by Benjamin Franklin), Phillips 66 and Oaktree Capital Management.

“This team is making discoveries through courageous innovation and positioning itself to make significant contributions to the health of our communities. I appreciate the opportunity to contribute to its continued success,” said Marna Whittington, PhD, newly appointed Director of Ocugen’s Board of Directors.

About Ocugen, Inc.
Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing gene therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (“SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:
Ken Inchausti
Head, Investor Relations & Communications
IR@Ocugen.com

NobleCon18 Presenting Companies

NobleCon18 Presenting Companies
April 19-21, 2022

REGISTER FREE AS AN INVESTOR  |  PRESENTING COMPANY INQUIRIES  |  CONFIRMED SPEAKERS  |  NOBLECON18.COM

Click the logos to view more information on each company
Click the preview link to watch a preview video from the presenter
New companies and preview videos are added regularly



ATNM (NYSE)
 

ALCO (NasdaqGS)
 

AUXXF (OTCQX)
 

ARLP (NasdaqGS)
 

ALVOF (OTCQX)
 

Aurox (Private)
 

ASM (NYSE)
Watch the Preview

AXLA (Nasdaq)
 

BCCEF (OTCPK)
Watch the Preview

BXRX (Nasdaq)
Watch the Preview

BBGI (Nasdaq)
Watch the Preview

BSGM (Nasdaq)
Watch the Preview

BLBX (Nasdaq)
 

BSFC (Nasdaq)
 

BOWL (Nasdaq)
 

CHKKF (OTCQB)
Watch the Preview

CING (Nasdaq)
 

CTXR (Nasdaq)
 

COCP (Nasdaq)
Watch the Preview

LODE (NYSE)
 

CMTL (NasdaqGS)
 

CMLS (Nasdaq)
 

CYDVF (OTCQB)
 

DMIFF (OTCQB)
 

DTGI (OTCQB)
 

DMS (NYSE)
 

DLHC (Nasdaq)
 

EGLE (NasdaqGS)
Watch the Preview

EEIQ (Nasdaq)
 

UUUU (NYSE)
 

GAME (Nasdaq)
 

EVC (NYSE)
Watch the Preview

EZFL (Nasdaq)
 

FGI (Nasdaq)
 

FLHLF (OTCQB)
Watch the Preview

FTK (NYSE)
 

OPA (NYSE)
Watch the Preview

VINE (NYSE)
Watch the Preview

GABLF (OTCQB)
 

GNK (NYSE)
 

GNPX (Nasdaq)
Watch the Preview

JETMF (OTC)
 

HHS (Nasdaq)
 

HCTI (Nasdaq)
Watch the Preview

HMNC (Private)
Watch the Preview

III (Nasdaq)
Watch the Preview

IPOOF (OTCQX)
 

INLB (OTCQX)
 

IZOZF (OTCQB)
 

JAGX (Nasdaq)
Watch the Preview

KELYA (NasdaqGS)
Watch the Preview

LEE (NYSE)
 

LCTX (NYSE)
 

LQWDF (OTCQB)
Watch the Preview

MGMLF (OTCQB)
Watch the Preview

M8G (ETR)
 

MMAT (Nasdaq)
 

MLSS (NYSE)
Watch the Preview

MSGM (Nasdaq)
Watch the Preview

NSCIF (OTCQX)
Watch the Preview

NMTC (OTCQB)
Watch the Preview

NRGOF (OTCQB)
 

OCGN (Nasdaq)
 

Odyssey Wellness
 

OSS (Nasdaq)
 

PRFX (Nasdaq)
Watch the Preview

PANL (Nasdaq)
Watch the Preview

KTTA (Nasdaq)
 

PENMF (OTC)
Watch the Preview

PYNKF (OTC)
Watch the Preview;

OILCF (OTCQB)
 

PSYCF (OTCQB)
Watch the Preview

RICK (Nasdaq)
Watch the Preview

RMTI (OTCQB)
 

SALM (Nasdaq)
Watch the Preview

SHWZ (OTCQX)
Watch the Preview

SMTS (NYSE)
Watch the Preview

SMFL (Nasdaq)
Watch the Preview

SBEV (NYSE)
 

SKYX (Nasdaq)
 

SURG (OTCQB)
 

GEO (NYSE)
 

TNXP (Nasdaq)
 

TSQ (NYSE)
 

VIVK (Nasdaq)
 

VNRX (NYSE)
 

VOXCF (OTCQB)
Watch the Preview

VYGVF (OTCQB)
 

WSNAF (OTCQB)
Watch the Preview

WRAP (Nasdaq)
 

BioSig Announces Closing of Public Offering of Common Stock



BioSig Announces Closing of Public Offering of Common Stock

News and Market Data on BioSig Technologies

 

Westport, CT, March 23, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the completion of its previously announced underwritten public offering of 2,611,739 shares of its common stock, $0.001 par value per share, at a price to the public of $1.15 per share. The proceeds to BioSig from this offering were $3 million.  The Company also issued a cash warrant at $1.40. Fully exercised the Company will receive another $3m of cash proceeds.

BioSig intends to use the net proceeds from the offering for the continuation of full commercialization activities related to the PURE EP™ System.

A shelf registration statement on Form S-3 (Registration No. 333-251859) relating to the public offering of the shares of common stock described above was previously filed with the Securities and Exchange Commission (“SEC”) and declared effective on January 12, 2021. A final prospectus supplement and accompanying prospectus describing the terms of the offering were filed with the SEC on July 6, 2021, and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from BioSig Technologies, Inc. 55 Greens Farms Road Westport, CT 06880 Attention: Vice President Administration.; email: lmikolaitis@biosigtech.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement. 

About BioSig Technologies 

BioSig Technologies is a medical technology company commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market conditions and the Company’s intended use of proceeds, (ii) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (iii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iv) difficulties in obtaining financing on commercially reasonable terms; (v) changes in the size and nature of our competition; (vi) loss of one or more key executives or scientists; and (vii) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. 

Andrew Ballou
Vice President, Investor Relations
BioSig Technologies, Inc.
55 Greens Farms Road
Westport, CT 06880
203 409-5444, x 133
aballou@biosigtech.com

Source: BioSig Technologies, Inc.

Voyager Digital (VYGVF)(VOYG:CA) – Volumes Below Expectations; Updated Model, Lowering PT to $15

Wednesday, March 23, 2022

Voyager Digital (VYGVF)(VOYG:CA)
Volumes Below Expectations; Updated Model, Lowering PT to $15

Voyager Digital Ltd through its subsidiary, operates as a crypto asset broker that provides retail and institutional investors with a turnkey solution to trade crypto assets. The company offers investors execution, data, wallet and custody services through its institutional-grade open architecture platform.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Challenging Environment. Cryptocurrency trading volumes continue to decline, as the Russia/Ukraine war, threatened legislation, and a weakening economy have raised concerns among investors in this new asset class. Data from The Block indicate trading volume in January fell to $833.6 billion from $1.04 trillion in December. February came in at $683.1 billion and March to date is just $469.8 billion. March could be the lowest month since December 2020.

    Updated Guidance.  As a result of the disappointing volumes, we have lowered our expectations for the second half of fiscal 2022. Revenue for the fiscal third quarter (ending March 31) is now projected at $98 million, down from a prior $113 million, while we reduced fourth quarter revenue to $116 million from $175 million on the assumption current trends do not improve significantly. As a result …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Item 9 Labs (INLB) – Unity Rd. Expanding into New Mexico

Wednesday, March 23, 2022

Item 9 Labs (INLB)
Unity Rd. Expanding into New Mexico

Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by 650,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New Mexico Entry. Yesterday, Item 9 Labs announced entry into the New Mexico market with the signing of an agreement that will bring three dispensaries to New Mexico. Unity Rd. recently helped the entrepreneurial group secure state approval for dispensary licenses of all three shops and will be assisting the team in moving forward with development. The group currently have confirmed local city approval in Ruidoso and are awaiting approval from two additional cities for development.

    New Mexico Market.  A medical cannabis market, the state has approved adult use recreational to begin no later than April 2022. The medical market is about $200 million, with adult use projected to add another $425 million within four years. Notably, there are only 35 vertically integrated businesses licensed in the state, operating about 125 dispensaries …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Gevo (GEVO) – Two SAF Commitments of 105 MGPY From Two Airlines

Wednesday, March 23, 2022

Gevo (GEVO)
Two SAF Commitments of 105 MGPY From Two Airlines

Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment and the Gevo Development/Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of isobutanol, including the development of its biocatalysts, the production and sale of biojet fuel, its Retrofit process and the next generation of chemicals and biofuels that will be based on its isobutanol technology. Gevo Development/Agri-Energy is the key revenue generating segment which involves the operation of the Luverne Facility and production of ethanol, isobutanol and related products.

Poe Fratt, Senior Research Analyst, Logistics, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Delta Air Lines (DAL) upsizes SAF commitment and another airline commits. DAL increased the sustainable aviation fuel (SAF) commitment to 75 MGPY from 10 MGPY, or an extra 65 MGPY, under a seven year agreement that represents potential revenue of $2.8 billion, including green and other credits. Also, a member of the oneworld Alliance has committed to buy 30 MGPY, which represents potential revenue of $800 million.

    Contracted FSA portfolio remains high and added contracts likely later this year.  While the two commitments move the contracted FSA portfolio to 194 MGPY from 99 MGPY, or potential revenue of ~$8.0 billion, other potential large commitments from CVX (up to 150 MGPY) and others remains on the horizon. The development pipeline remains very high at more than 1,500 MGPY, or revenue potential in excess …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

 

Digerati Technologies (DTGI) – A Surprising Reaction To A Solid Quarter Raising Price Target

Tuesday, March 22, 2022

Digerati Technologies (DTGI)
A Surprising Reaction To A Solid Quarter; Raising Price Target

Digerati Technologies, Inc. (OTCQB: DTGI) is a telecom and technology provider of diverse, carrier-grade, Only in the Cloud™ communication and network solutions including Unified Communication as a Service, cloud telephony, cloud WAN, cloud call center, cloud mobile, and delivery of digital oxygen on its fiber/mobile broadband network. Digerati has developed a robust integration platform to fuel mergers and acquisitions in a highly fragmented market as it delivers flexible, cost-effective services with enterprise-grade quality and reliability. A multi-year recipient of Deloitte’s Fast500 and Fast50 Awards for one of the fastest growing technology companies in North America, Digerati has become an expert at successfully merging and managing subsidiary operations since 2015. The Company’s impressive tech-stack serves 28,000 business users on its platform and its dynamic channel program includes over 300 channel partners that serve as a conduit for sales growth. Digerati has continuously increased customer adoption while serving diverse industries including Healthcare, Banking, Financial Services, Legal, Real Estate, and Construction. Digerati currently has a strong platform for growth throughout Texas and Florida, the 2nd and 4th largest state economies by GDP in the U.S. The Company’s clean and clear fundamentals, combined with its clearly defined growth plan, disciplined acquisition strategy and seasoned leadership team is expected to increase shareholder value as it enters the next phase of its corporate development plan. For more information, please visit www.digerati-inc.com.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Solid Q2 results.  Digerati reported better than expected fiscal second quarter end January 31 results, with total company revenues of $4.019 million, versus our $3.790 million estimate. Adj. EBITDA was also better than expected at $0.364 million versus our $0.309 million estimate. The results benefited from one month contribution from the Skynet acquisition, but results were better than expected after adjusting for that contribution.

    Executing the roll-up strategy.  The company has completed two acquisitions since the start of the year, SkyNet Telecom and Next Level. These acquisitions have augmented its customer reach in Texas and expanded operations into California. and now serves over 4,000 business customers and 45,000 users …


This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.